Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
DATA GRAPHICS | Finance

CRISPR stocks continue ascent on Intellia data: Data Byte

Editas, CRISPR Therapeutics follow Intellia higher after breakthrough data

July 3, 2021 2:36 AM UTC

Stocks of the three publicly traded CRISPR therapeutics companies with access to the technology’s foundational IP continued their rise throughout the week following the first clinical data for a systemically delivered CRISPR therapy from Intellia on Saturday.

Shares of Intellia Therapeutics Inc. (NASDAQ:NTLA), which gained about $3 billion in market cap on Monday, finished the week up $74.88 (84%) to $163.71, representing a gain of over $5 billion in market cap since last Friday. The company, which now has a market cap of more than $11 billion, followed the data by raising a $690 million follow-on, the largest such offering so far this year on NASDAQ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article